-
Evaluating the Cost-Effectiveness of Wastewater-Based Disease Surveillance
Mar 10, 2025, 14:00 PM -
Assessing the Impact of Digital Ecosystem Engagement on Outcomes in Sickle Cell Disease (SCD) Patients
Mar 10, 2025, 14:00 PM -
Cost-Utility Analysis of Dupilumab Versus Omalizumab in the Treatment of Severe Asthma in China
Mar 10, 2025, 14:00 PM -
Exploring Mobile and Wearable Technology for Early Depression Detection and Monitoring
Mar 10, 2025, 14:00 PM -
Selection and Stability of Parametric Bivariate Copula Models for Joint Modelling of Overall and Progression-Free Survival
Mar 10, 2025, 14:00 PM -
The Relationship Between Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma: A Meta-Regression of Clinical Trial Data
Mar 10, 2025, 14:00 PM -
Adoption of a Drug Adherence-Enhancing Application To Achieve Optimal Medication Adherence and Blood Pressure Control Among Hypertensive Patients: A Randomized Controlled Trial
Mar 10, 2025, 14:00 PM -
Beyond Overall Survival: Advancing the Understanding and Use of Surrogate Endpoints in Oncology
Mar 10, 2025, 14:00 PM -
Examining Patterns in Breast Cancer Patient Characteristics and Treatment Throughout the COVID-19 Pandemic
Mar 10, 2025, 14:00 PM -
Progression-Free Survival and Objective Response Rates As Surrogate Endpoints for Overall Survival Among Patients With ROS1+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer Receiving ROS1 Tyrosine Kinase Inhibitors
Mar 10, 2025, 14:00 PM -
The Most Heavily Managed Drug Categories on Part D Formularies
Mar 10, 2025, 14:00 PM -
Exploring Treatment Preferences for Rare Diseases: A Systematic Review of Quantitative Preference Studies
Mar 10, 2025, 14:00 PM -
Cost Opportunity of Polatuzumab Vedotin as First-Line Therapy for DLBCL on Subsequent Treatments - Brazilian Cost Analysis
Mar 10, 2025, 14:00 PM -
Racial Disparities and the Impact of Access Restrictions to Apixaban in Part D
Mar 10, 2025, 14:00 PM -
Economic Burden of Non-Pharmacological Treatment in Amyotrophic Lateral Sclerosis in Brazil's Public Healthcare System: A 2022 Real World Cost Analysis
Mar 10, 2025, 14:00 PM -
A Critical Review of Existing Shared Decision-Making Measuring Approaches in Studies Using the Medical Expenditure Panel Survey (MEPS)
Mar 10, 2025, 14:00 PM -
Treatment Patterns and Efficacy/Safety of the Drugs in HER2+ NSCLC: A Systemic Literature Review
Mar 10, 2025, 14:00 PM -
Potential Added Clinical Value of Polygenic Risk Scores in Risk Assessment of Atherosclerotic Cardiovascular Disease
Mar 10, 2025, 14:00 PM -
Medicare Spending on Orphan Drugs With Single and Multiple Rare Disease Indications
Mar 10, 2025, 14:00 PM -
A Cluster Analysis to Identify Predictors and Profiles of Financial Hardship Among Cancer Patients in the United States
Mar 10, 2025, 14:00 PM
